Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
$2.71
-2.2%
$2.42
$1.78
$8.58
$57.87M0.7246,974 shs101,203 shs
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
$11.50
+15.0%
$8.15
$5.01
$18.71
$59.61M0.18117,501 shs158,291 shs
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
$0.20
$0.17
$2.96
$13M-25.84N/AN/A
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
$16.55
+2.4%
$16.90
$12.12
$26.99
$53.57M0.5822,537 shs1,431 shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
0.00%+9.06%+23.11%+1.47%-66.10%
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
0.00%+8.34%+25.94%+62.87%-9.17%
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
0.00%0.00%0.00%0.00%-56.53%
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
0.00%-1.41%+7.81%-14.74%-17.79%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
4.253 of 5 stars
3.44.00.04.80.62.50.6
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
4.2189 of 5 stars
3.43.00.04.70.63.30.6
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
N/AN/AN/AN/AN/AN/AN/AN/A
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
1.5645 of 5 stars
3.52.00.00.02.30.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
2.80
Moderate Buy$23.80778.23% Upside
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
2.83
Moderate Buy$20.0073.91% Upside
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
0.00
N/AN/AN/A
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
3.00
Buy$35.50114.49% Upside

Current Analyst Ratings Breakdown

Latest CHHE, ADVM, ATRA, and VTVT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/26/2025
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$16.00 ➝ $12.00
5/15/2025
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Perform ➝ Sector Perform$5.00 ➝ $4.00
5/15/2025
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$33.00 ➝ $33.00
5/15/2025
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
(Data available from 7/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
$1M56.61N/AN/A$3.40 per share0.80
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
$128.94M0.53N/AN/A($16.89) per share-0.68
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
$110K0.00N/AN/AN/ANaN
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
$1.02M51.76N/AN/A$4.48 per share3.69
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
-$130.93M-$6.40N/AN/AN/AN/A-130.53%-66.31%8/11/2025 (Estimated)
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
-$85.40M-$3.72N/AN/AN/A-7.83%N/A-14.51%8/11/2025 (Estimated)
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
-$410K-$0.020.00N/AN/AN/AN/AN/AN/A
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
-$18.46M-$3.01N/AN/AN/A-121.46%-46.75%8/6/2025 (Estimated)

Latest CHHE, ADVM, ATRA, and VTVT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025N/A
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
-$0.85N/AN/AN/AN/AN/A
8/11/2025Q2 2025
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
-$2.24N/AN/AN/AN/AN/A
8/11/2025Q2 2025
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
-$0.32N/AN/AN/A$4.23 millionN/A
5/15/2025Q1 2025
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
-$3.07$3.50+$6.57$3.50$4.30 million$98.10 million
5/15/2025Q1 2025
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
-$0.73-$0.77-$0.04-$0.77N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
N/AN/AN/AN/AN/A
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
N/AN/AN/AN/AN/A
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
N/AN/AN/AN/AN/A
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
N/A
3.57
3.57
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
N/A
0.57
0.57
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
N/AN/AN/A
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
N/A
7.39
7.39

Institutional Ownership

CompanyInstitutional Ownership
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
48.17%
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
70.90%
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
N/A
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
17.51%
CompanyEmployeesShares OutstandingFree FloatOptionable
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
19020.89 million19.64 millionOptionable
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
3305.96 million5.72 millionOptionable
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
4064.95 million44.62 millionNot Optionable
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
93.19 million3.15 millionNot Optionable

Recent News About These Companies

vTv resumes Phase III oral T1D drug study
vTv Therapeutics initiated with a Buy at H.C. Wainwright
vTv Therapeutics reports Q4 EPS (55c) vs ($1.67) last year
vTv Therapeutics stock surges on FDA update

New MarketBeat Followers Over Time

Media Sentiment Over Time

Adverum Biotechnologies stock logo

Adverum Biotechnologies NASDAQ:ADVM

$2.71 -0.06 (-2.17%)
Closing price 04:00 PM Eastern
Extended Trading
$2.71 0.00 (0.00%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Atara Biotherapeutics stock logo

Atara Biotherapeutics NASDAQ:ATRA

$11.50 +1.50 (+15.00%)
Closing price 04:00 PM Eastern
Extended Trading
$11.60 +0.10 (+0.87%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

China Health Industries stock logo

China Health Industries OTCMKTS:CHHE

China Health Industries Holdings, Inc., through its subsidiaries, manufactures and sells health products. The company operates through three segments: Humankind, HLJ Huimeijia, and Others. The company offers hemp derivative products, such as hemp oil, hemp protein powder, hemp polypeptides, collagen peptides, hemp essence repair lotions, hemp revitalizing essence products, hemp anti-aging brightening eye creams, hemp frozen age nourishing creams, hemp seed beers, and hemp seeds. It also provides health supplements, including Sailuozhi soft capsule, which is made from frog oil, soybean isoflavone, procyanidine, and vitamin E for freckle removal and skin moisture supplements under the QunLe brand; and propolis and black ant capsule that is made from propolis, black ant, acanthopanax, and astragalus root under the Kindlink brand. In addition, the company offers health products for acne removal, relieving eyestrain, enhancing bone density, enhancing memory, enhancing nutritional anemia and chloasma, relaxing bowels and promoting the discharge of lead, enhancing immunity and relieving physical fatigue, and dispelling chloasma, as well as iron and multivitamin, and mineral supplements. Further, it manufactures and sells various types of medical drugs, such as enema glycerini, umguentumacidi borici camphoratum, ge hong beriberi water, pelvic inflammation suppository, injury and paralysis tincture, indometacin and furazolidone suppositories, injury and rheumatism relieving paste, refining goupi cream, muskiness pain relieving paste, muskiness bone strengthener paste, matrine suppositories, ethacriding lactate solution, iodine tincture, mercurochrome solution, hydrogen peroxide solution, halcinonide cream, compound fluocinonide tincture, and policresulen vaginal suppository. The company primarily sells its products through sales personnel and sales agents. China Health Industries Holdings, Inc. was founded in 1996 and is based in Harbin City, the People's Republic of China.

vTv Therapeutics stock logo

vTv Therapeutics NASDAQ:VTVT

$16.55 +0.39 (+2.42%)
Closing price 03:57 PM Eastern
Extended Trading
$16.52 -0.04 (-0.22%)
As of 06:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 inhibitor, which is in Phase III trial for the treatment of psoriasis, COPD, and atopic dermatitis, as well as TTP-RA, a RAGE antagonist for type 1 diabetes prevention. In addition, the company's other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress; and Azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for glioblastoma, other cancers, and cancer treatment-related conditions. vTv Therapeutics Inc. has license agreements with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593 for therapeutic, prophylactic, and diagnostic application; and Anteris Bio, Inc. to develop and commercialize HPP971, a Nrf2 activator, as well as with Cantex Pharmaceuticals, Inc.; Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.